Published in final edited form as:

Curr Osteoporos Rep. 2018 August ; 16(4): 490–503. doi:10.1007/s11914-018-0458-4.

Origin of Reparative Stem Cells in Fracture Healing

Beth C Bragdon¹ and Chelsea S Bahney²

¹Department of Orthopaedic Surgery, Boston University School of Medicine, Boston, MA 02118, USA

²Orthopaedic Trauma Institute, Department of Orthopaedic Surgery, University of California, San Francisco (UCSF)

Abstract

Purpose of review—The identity and functional roles of stem cell population(s) that contribute to fracture repair remains unclear. This review provides a brief history of mesenchymal stem cell (MSCs) and provides an updated view of the many stem/progenitor cell populations contributing to fracture repair.

Recent findings—Functional studies show MSCs are not the multipotential stem cell population that form cartilage and bone during fracture repair. Rather, multiple studies have confirmed the periosteum is the primary source of stem/progenitor cells for fracture repair. Newer work is also identifying other stem/progenitor cells that may also contribute to healing.

Summary—Although the heterogeneous periosteal cells migrate to the fracture site and contribute directly to callus formation, other cell populations are involved. Pericytes and bone marrow stromal cells are now thought of as key secretory centers that mostly coordinate the repair process. Other populations of stem/progenitor cells from the muscle and transdifferentiated chondrocytes may also contribute to repair, and their functional role is an area of active research.

Keywords

Skeletal Stem cell; Fracture; Mesenchymal Stem Cell; Periosteum; Pericyte

Defining Stem Cells

Stem cells are defined as having the ability to differentiate to specialized cell types and being capable of self-renewal, such that some fraction of the progeny remains undifferentiated. Based on the differentiation potential, or “potency” of the stem cell, they can be classified as totipotent, pluripotent, multipotent, or unipotent. Totipotent describes stem cells that are able to generate all of the cell fates of the animal including the extraembryonic tissues, such as the placenta. These are the zygote and early blastomeres. Pluripotent cells, also called embryonic stem cells (ESCs), are able to generate the embryonic tissues from all three primary germ layers and are isolated from the inner cell mass of the blastocyst. In addition to these native pluripotent stem cells, it is also possible to experimentally derive a

pluripotent stem cell population from adult somatic cell. These “induced” pluripotent stem cells (iPCS)^{1,2} are generated by genetically reprogramming cells: the technology was named the Nature Method of the Year in 2009 and Yamanaka/Gurdon received the Nobel Prize 2012 for their discovery.

Once stem cells lose the ability to form all cell types they are considered multipotent. Multipotent cells generate a limited number of cell fates of an animal in closely related families of cells, for example, all the tissues within a specific germ layer or organ system. Tissue specific stem cells are known as “adult” or “somatic” stem cells, and are somewhat specialized to generate multiple, organ specific cell types. Adult stem cells are located in specialized niches that maintain the stemness through interaction with the local microenvironment. These stem cells contribute to tissue homeostasis and injury response.

The musculoskeletal system supports a number of multipotent adult stem cells. The best characterized adult stem cell population is the hematopoietic stem cell (HSC), which is the source for all blood cells. HSCs are localized and maintained within the bone marrow. Also located in this niche, are the bone marrow stromal cells (BMSCs), also known as mesenchymal stem cells (MSCs) or skeletal stem cell (SSC). As discussed later in the review, there remains disagreement as to the definition and biological role of these cells in the adult animal.

Lastly is the unipotent stem cell, which is able to generate only a single cell fate. There is some debate within the field on whether unipotent stem cells should be considered “stem cells” or if “stem cells” must have the capacity to differentiate into multiple cell types. Within the musculoskeletal system, satellite cells are unipotent progenitors that have self-renewal capacity, but only give rise to muscle cells.

While differentiation capacity is defining characteristic of a stem cell, to be considered a bonafide stem cell it must also have self-renewing properties. Experimentally it is much more difficult to demonstrate self-renewing properties. The gold standard for experimentally demonstrating self-renewal is *in vivo* implantation and serial transplantation.³ This involves isolating the discrete cell population of interest followed by implantation and following the formation of ectopic tissue. This provides the initial *in vivo* evidence that the cell population of interest can give rise to *de novo* tissues. Next, self-renewal capacity must be shown through re-isolation of the cell population from this *de novo* tissue, followed by a second implantation demonstrating subsequent *de novo* tissue formation. In the case where self-renewal has not been experimentally demonstrated it is more accurate to use the term “progenitor” cell to describe the cell population. Progenitor cells are an intermediate between the stem cell and specialized cell, have a high proliferative capacity, and are non-self-renewing.

This review will focus on the endogenous stem and progenitor populations that contribute to fracture repair. Bone is unique within in the musculoskeletal system in that under normal conditions a broken bone can truly regenerate; producing a *de novo* tissue that is indistinguishable from the original, in form and function. We aim to present current perspective on both the individual cell types involved in bone regeneration and how cross-

talk between cell populations coordinates healing. Importantly, this review aims to highlight the many unanswered questions and areas of ongoing debate that relate to the type and location of these different stem and progenitor cell populations.

The “MSC”

The history and debate

Some of the earliest studies aimed at bone regeneration is by Urist in 1965 where he was able to induce heterotopic ossification (HO) or *de novo* bone formation in the musculature of animals by implanting demineralized bone.⁴ Later studies by Urist first identified Bone Morphogenetic Proteins (BMPs) as the key protein driving HO development.^{5,6} However, it was Tavassoli and Crosby that originated the concept that a population of adult “stem cells” respond and give rise to the *de novo* bone formation also in the 1960s. Their experiments showed that boneless fragments isolated from the bone marrow could be transplanted into multiple heterotopic sites and produce HO. The size of the HO appeared to depend upon the amount of isolated tissue implanted.^{4,7} It was concluded that the bone marrow must consist of an entity that had osteogenic potential. This work was followed by Friedenstein *et al* who continued this work from late 1960’s to 1990. During this time, he isolated the bone marrow derived “stem cell” and demonstrated osteogenic capacity. The osteogenic potential of these cells were non-hematopoietic, tissue culture plastic adherent cells, and were clonogenic in culture at low density. Further, transplantation of a single clonogenic cell had multipotent potential and could generate a variety of tissues in addition to bone, including, cartilage, adipocytes and fibroblasts.^{8–14}

In 1990, Arnold Caplan coined the term “mesenchymal stem cell”, or MSCs, to describe these multipotent progenitor cells with the capacity to form adipose, cartilage, and bone tissue or the “ABCs”.^{15,16} The mesenchymal stem cell theory originated and developed from the idea that during embryogenesis the mesoderm consists of multipotent progenitors that will give rise to bone, cartilage, muscle, and other mesenchymal tissues. Similarly, cells from the bone marrow had osteogenic potential *in vivo* and were shown to differentiate into multiple lineages such as bone, cartilage, tendon, muscle, and fat *in vitro*.

Through Caplan’s work, along with others, it was thought that these MSCs were perhaps more broadly distributed throughout the body rather than located solely within the bone marrow. Progenitor cells showing similar *in vitro* differentiation potential to the bone marrow derived MSCs have subsequently been isolated from adipose tissue¹⁷, periosteum^{18,19}, the synovial lining^{20,21}, and muscle^{22,23} tissue. Crisan *et al* later demonstrated that MSCs expressed similar markers with pericytes (cells located on the abluminal surface of vessels) and that pericytes had equivalent multipotent properties *in vitro*.^{24,25} This suggested that MSCs were pericytes and perhaps explains how they can be isolated from many tissues. Caplan wrote in an article to accompany the Crisan paper that “...my suggestion is all MSCs are pericytes...”²⁶

We would like to point out that not all pericytes are MSCs and that experimentally there are inherent differences between MSCs isolated from different tissues.^{26–28} This may be explained by the fact that the multipotency of these cells has only been rigorously

demonstrated *in vitro*. As such it remains unclear, and actively debated, whether the perivascularity is another MSC niche, if they are the same cell, or if pericytes represent some MSC precursor population. However, the previous studies from 1960's and 70's showing bone marrow stromal cells capable of forming ectopic bone *in vivo*, suggests a presence of a stem cell or tissue specific progenitor(s), that are more lineage restricted than the 1990 Caplan postulated MSC.^{29–31} Current research suggests that tissue specific progenitor cell populations may actually contribute to the pericyte fate²⁷ providing a possible link with pericytes.

Despite remaining uncertainty over the true multipotency of the MSC, recent work has suggested that *in vivo* MSCs function as secretory centers rather than a progenitor population.^{32,33} Rather, the current model postulates that injury activates MSCs/pericytes to migrate away from vessels and become activated to secrete factors that promote local tissue regeneration.^{32,34–38} A specific population of MSCs/pericytes did not contribute to tissue homeostasis over a two-year period or contribute to the regeneration after injury (brain, heart, and muscle)³⁹. A secretome of the MSCs has been demonstrated as both trophic and immunomodulatory, in that it can stimulate tissue repair by activating local progenitor cells and secreting anti-inflammatory cytokines. In fact in 2017, Caplan purposed to change the name of “Mesenchymal Stem Cell” to “Medicinal Signaling Cell” due to their main function as signaling centers during injury^{40,41}.

MSC identity

When using the term MSCs, details of the cell population one is referring to should be clearly defined, as history shows there is discrepancy in naming convention. Naming convention is challenged by a lack of consensus over the cell surface markers for a “MSC”. Moreover, there appears to be a species-specific differences, with possible differences in cell surface markers between human and mouse MSCs. In 2006 the International Society of Cellular Therapy published a proposed minimal criteria for multipotent MSCs, they suggested: cells must be adherent to plastic, show multipotent differentiation *in vitro* to osteoblasts, adipocytes, chondrocytes, and have specific surface antigen expression for CD105, CD73, and CD90 while negative for CD45, CD35, CD14, CD79alpha, and HLA-DR. (Table 1)

Stem Cell Contribution to Fracture Repair

Molecular and Cellular Overview

Bone has a high regenerative capacity and the majority of fractures will heal with a tissue that is indistinguishable from the native tissue in form and function. One reason for the reparative nature of bone is the existence of many active local progenitor cells connected systemically through networks of vascularity. Fracture healing proceeds through four biologically distinct, but overlapping phases – inflammation, intramembranous ossification, endochondral ossification, bone remodeling – with stem cells differentially contributing to each stage of healing.

The cascade of bone regeneration begins when the bone breaks. This exposes the bone marrow and results in rapid formation of a hematoma to contain the bleeding and help debride the injury. In this first phase of repair, a pro-inflammatory response dominates healing through activation of neutrophils, macrophages, and other inflammatory cells. While a prolonged pro-inflammatory state can have a negative effect on bone repair, the early pro-inflammatory response influences differentiation and establishment of the initial fracture callus.^{42–47}

The progenitor cells that heal the fractured bone come locally from the endosteum and periosteum.^{29,48–50} These progenitor cells respond to the fracture by upregulating genes associated with proliferation, as well as numerous cytokines and chemokines that help enable osteogenic or chondrogenic differentiation.⁵¹ Importantly, differentiation of these stem cells is mechanically sensitive and the relative stability of the microenvironment drives fate decisions.^{52–55} Along the endosteal and periosteal surfaces, where the bone itself provides a high degree of stability, the progenitor cells differentiate directly into osteoblasts and contribute to fracture repair through intramembranous bone healing. In the fracture gap, where there is more mobility, periosteal progenitor cells differentiate into chondrocytes to form a soft cartilage callus to provide a temporary bridge between the broken bone ends.

The endochondral phase of healing describes the process by which this soft cartilage callus becomes bone. During this phase of healing it is important that the pro-inflammatory state is resolved or healing can be delayed.^{44,45,47,56} Macrophage polarity is critical towards regulating the inflammatory microenvironment and resolution involves modulating from the pro-inflammatory “M1” macrophages towards an anti-inflammatory “M2” state.

As endochondral healing proceeds the soft cartilage callus is replaced by bone through a combination of chondrocyte to osteoblast transformation and new bone formation. It was once believed that hypertrophic chondrocytes were fated for cell death^{57,58}, but now there is a preponderance of new data using modern genetic tools demonstrating chondrocytes can give rise directly to osteoblasts during development, growth, and repair.^{59–65} While data suggests that chondrocytes give rise to the majority of osteoblasts during fracture healing^{59,60}, pericytes or invading osteochondral progenitors from the vasculature may also contribute to the new bone formation from the cartilage template⁶⁶.

The final stage of fracture healing involves conversion of the newly formed woven bone to a cortical bone structure. Bone resorption is tightly coupled to bone formation and required for functional healing. Osteoclasts are the multinucleated giant cells responsible for resorption.⁶⁷ Osteoclast mediated degradation of the bone releases matrix-sequestered factors, such as TGF β , as well as factors produced by the osteoclast itself, such as complement 3a, which are both hypothesized to be critical in the subsequent stimulation of osteogenesis^{68,69}. Osteoclast mediated bone resorption is concluded with the apoptotic death of the osteoclasts.
70

While the initial fracture callus is established by osteochondral progenitor cells from the periosteum and endosteum, multiple other progenitor populations influence their differentiation and coordinate their ultimate phenotype. In the sub-sections below we aim to

describe the contribution and cross talk between various progenitor populations and experimental tools for continuing to investigate their role in fracture repair. FIGURE 1

Periosteal Progenitor Cells

Covering the surfaces of bone is a highly-vascularized bilayer membrane called the periosteum. In the outer most layer of the periosteum, collagens and elastin provide fibrous structure that assists in regulating the flow of molecules between bone and muscle.^{71,72} The inner most layer consists of the progenitor cells that contribute to bone homeostasis and fracture repair. The cellular response to fracture within the periosteum is observed as early as 24–48 hours post-injury through rapid proliferation. While the disruption of the periosteum has been shown to delay fracture repair⁷³, the specific identification of the population(s) of progenitor cells that reside within the periosteum is still unclear. Functional studies suggest that periosteal progenitors are bipotent, with an osteochondral potential⁴⁸, and that they express some MSCs cell surface markers: CD73, CD90, and CD105.^{52,72,74,75}

Elegant studies by Celine Colnot used the combination of bone grafting and lineage tracing to show that periosteal and endosteal cells are functionally distinct.⁴⁸ Using reporter animals as donors for bone grafts, it was shown that the endosteum has only an osteogenic potential, while, the periosteum has both osteogenic and chondrogenic potential. This characteristic appears intrinsic to the cell populations. This was experimentally supported by demonstrating a differential response of periosteal and endosteal cells to BMP; where the chondrogenic potential of endosteal cells is significantly reduced given exogenous application of BMP.⁷⁶ This differing response to BMP signaling in the periosteal cells is further supported by an interesting study by Morgan *et al* where BMP signaling was inhibited using a soluble form of the BMP receptor type Ia. Only the periosteal response was blunted, cartilage maturation was delayed and periosteal bone bridging was decreased resulting in impaired strength and toughness. Although other cell populations showed an osteogenic response with increased osteogenic gene response and mineralized tissue.⁷⁷

Using reporter mice Prx1 has been identified as a periosteal marker, first identified by expression in mesenchymal cells during embryological development of the limb.^{29,78–80} Studies in the adult animal later showed Prx1 expression in the periosteum and suggested they represent a population of progenitor cells that contributes to the fracture callus.^{29,49} Knockout of BMP2 in Prx1-Cre cells in the limb mesenchyme resulted in spontaneous fractures in adults and a lack of callus formation.⁸¹ Within the periosteum, a subset of cells along the perivascular domain that were labeled by α SMA, were also found to give rise to the fracture callus.^{50,82} Characterization of these α SMA⁺ cells from the periosteum revealed a very heterogeneous population that expresses different markers of MSCs (Sca1 (9% of cells), PDGFR α (2%), Leptin receptor (2%), and pericytes (PDGFR β (2%)). Taken together these studies indicate a heterogeneous periosteum where the cell populations have a distinct function and potential from other progenitor cells.

MSCs

Because of the excitement generated over the discovery of the “MSC”, and their multipotent capacity to form cartilage and bone *in vitro*, it is often falsely assumed that bone marrow

derived MSCs are the primary cells that heal bone. This misconception is fueled clinically by therapeutic application of BM-MSCs to promote bone regeneration. However, as discussed above, and rigorously demonstrated experimentally, periosteal progenitors are the primary source of cells that give rise directly to fracture callus. Importantly, it has been shown experimentally that bone marrow derived cells have a very minimal direct contribution to fracture healing using bone marrow ablation/transplantation.^{44,83}

While BM-MSCs may not play a direct role in forming the fracture callus that heals the bone, they none-the-less play an important role in supporting healing through paracrine secretion of trophic and immunomodulatory factors. The “trophic”, or a stimulatory influence, of MSCs on other cells is another term that has been famously coined and promoted by Caplan.³² Secretory molecules produced by MSCs that influence tissue resident progenitor cells include, TGF- β , stem cell factor (SCF), insulin-like growth factor (IGF), epidermal growth factor (EGF), and granulocyte and macrophage colony stimulating factors (G/M-CSF).^{32,33} Current evidence suggests that these paracrine trophic factors, rather than direct differentiation and engraftment of MSCs^{32,84–87}, are responsible for observed repairs following MSC therapy in disease conditions such as stroke^{88,89}, osteogenesis imperfecta⁹⁰, myocardial infarct⁹¹, and fracture repair^{92,93}.

In addition to this trophic role, MSCs are key regulators of local inflammation during fracture repair. As mentioned above, transition from a pro- to anti-inflammatory state is critical for stimulating both initial differentiation of the periosteal progenitor cells and transition from cartilage to bone during endochondral ossification.^{42–47} Specifically, macrophages are a key cell population that contribute to polarizing the inflammatory state and MSCs have an immunomodulatory effect on macrophages. The mechanism(s) by which MSCs polarize macrophages remains an active area of research. While it is established that paracrine regulation of the macrophage polarity can be achieved by secretion of factors such as IL-10, IL-13, IL-4, and TGF β , there may also be direct interaction of these cell types.^{32,84,94–96}

Tracking the *in vivo* fate and contribution of tissue resident MSCs and/or pericytes to fracture healing is complex and has been limited to studies that can identify novel cell populations by *in vivo* markers and subsequent functional studies. Within the bone marrow, “MSC-like” cells that contribute to bone regeneration with unipotent potential towards the osteogenic lineage were identified by expression of myxovirus resistance-1 (Mx-1).³⁰ These Mx1-cells were shown to have clonogenic capacity, single cell-derived multilineage differentiation capability *ex vivo*, and *in vivo* osteogenic differentiation and new bone formation after transplantation.³⁰ Work from Ivo Kalajzic’s group has demonstrated a set of α SMA⁺ cells located in the perivascular region of the periosteum, bone marrow, and muscle.^{50,82} *In vitro* α SMA⁺ cells have multilineage potential and *in vivo* α SMA-CreERT::Ai9 contribute directly to the bone and cartilage callus formed during fracture healing.⁵⁰ Continued work in these reporter systems will help to clarify a both the cellular contribution and functional role for these “MSC” populations during fracture healing and help to define the relationship of these cells to other progenitor populations (Table 2).

Cartilage to Bone Transition in the Fracture callus

Formation of the cartilage callus by the periosteal cells is functionally important towards rapidly stabilizing the two bone ends. This provisional cartilage callus forms rapidly within the fracture gap, around days 5–7 in a mouse, and has been postulated to serve an evolutionary role in minimizing weight bearing until healing has been completed. Chondrocytes within this fracture callus proliferate and mature to hypertrophy through molecular signaling mechanisms presumed to parallel endochondral ossification in the growth plate.⁹⁷

Our understanding of the process by which bone forms from the cartilage callus is evolving. Previously, it was understood that hypertrophic chondrocytes underwent programmed cell death and that bone was formed by osteoprogenitors that invaded and remodeled the provisional cartilage matrix.^{58,66,98} While multiple earlier studies had suggested that chondrocytes could become osteoblasts^{99–104}, it is only recently that modern murine genetics has enabled lineage tracing to demonstrate that chondrocytes can give rise directly to bone through cellular transformation or transdifferentiation^{59–65}.

The mechanisms by which hypertrophic chondrocytes become osteoblasts remains unclear. Chondrocytes have been suggested to “de-differentiate” when cultured *in vitro* as early as 1960 and these “de-differentiated” chondrocytes could reexpress specific collagen genes to show a differentiated phenotype again.^{105,106} Later, Song and Tuan¹⁰⁷ suggested this enabled transdifferentiation *in vitro*. More recently, a few *in vivo* studies found expression of the pluripotency transcription factors during fracture healing.^{51,59,60} In particular, Hu *et al.* identified Sox2 at the osteochondral transition of the fracture callus using immunohistochemistry and genetic labeling in hypertrophic chondrocytes, and importantly, showed that conditional deletion of Sox2 impaired fracture healing by producing a significantly smaller callus with a decreased bone and increased cartilage fraction.⁶⁰ Outside of fracture repair, Sox2 has been identified as a marker of the adult stem cell niche and found to maintain multipotency and cell proliferation.^{108–112} While no studies to date have rigorously tested if hypertrophic chondrocytes meet the technical requirement of a “stem cells”, in the sense that they multipotent potential, hypertrophic chondrocytes at the chondro-osseous boarder have been shown to re-enter the cell cycle prior to transdifferentiation as evident by BrdU incorporation^{60,113}, and may be capable of asymmetric cell division^{103,114}.

Irrespective of whether hypertrophic chondrocytes in the fracture callus take on some sort of ‘stem cell like state’ to become more plastic, it is clear that these cells switch their genetic profile to become more osteoblastic.^{60,115,116} The Wnt/ β -catenin pathway appears to be particularly central to this genetic transformation. At a molecular level, chondrogenic (Sox9) versus osteogenic differentiation (Runx2, Wnt/ β -catenin) is regulated by direct repression of the opposing pathway.^{117–120} Functionally, two important studies have shown that genetic deletion of β -catenin from chondrocytes in the developing bone causes a severe decrease in trabecular bone formation and changes to osteoclastogenesis, while overexpression of β -catenin causes ectopic or accelerated bone formation.^{65,121,122} In fracture repair, immunohistochemistry has shown β -catenin and Runx2 are activated in hypertrophic chondrocytes at the fracture callus. Further, promoting activation of β -catenin through PTH

treatment during fracture repair, increased not only chondrogenic proliferation and differentiation, but also Runx2 and Osterix expression. The resulting callus was larger with significantly increased total bone volume.¹²³

Vasculature and Pericytes

The vasculature contributes to post-natal skeletal repair through both indirect and direct mechanisms. At a fundamental level, the vasculature is necessary for providing a permissive repair environment. This includes bringing in oxygen and nutrients, carrying away waste, and bringing in the immune cells that initiate a healing response. Angiogenesis, or new blood vessel formation, is critical for proper healing and impaired blood flow is often linked with poor clinical outcomes.^{124–126} These new blood vessels typically form at the regenerative front of well healing tissues like bone, and the vascular endothelial cells have been shown to secrete trophic factors that promote osteogenesis.^{59,76,127} Secreted factors from the vascular endothelial cells may also play a role in stimulating stem cells within their niche to enter a regenerative state by promoting Sox2 expression.⁶⁰

In addition to this direct role of the vasculature in supporting repair, blood vessels also provide the structural basis for pericytes. Following injury, pericytes are thought to enter the injured tissue in an activated state, where they serve a trophic function of providing growth factors to drive tissue regeneration and also play an anti-inflammatory role.^{32,36,37} Although the complete array of cytokines and growth factors that are secreted during injury is not known to date, it was shown that even cultured human pericytes (passages 1–10) secrete high levels of heparin binding epidermal growth factor, basic fibroblast growth factor, platelet derived growth factor-B chain, vascular endothelial growth factor, keratinocyte growth factor, and thrombopoietin which all have been related to repair.¹²⁸ And observations showed that BMP2 and VEGF protein increased with the regenerated bone due to the implantation of human perivascular cells at a critical calvarial bone defect.⁹² During repair pericytes also support angiogenesis by structurally facilitating tubule formation and vascular remodeling.

At least two pericytes markers have become fairly well established using *in vivo* lineage tracing studies in other fields, platelet derived growth factor receptor- β (PDGFR β)^{24,25,129} and neuro-glial 2 proteoglycan (NG2)¹³⁰, and many others have been suggested¹³¹. To date these pericytes-reporters have not been used to study *in vivo* fate during fracture healing. However, these pericyte markers along with mesenchymal stem cell markers (CD146, CD44, CD73, CD90, CD105)²⁵ has enabled the purification of pericytes populations for mechanistic data on the functionality of pericytes during skeletal tissue repair. For example, it has been shown that cultured purified human pericytes isolated from various tissues (skeletal muscle, pancreas, adipose, and bone marrow) are capable to differentiate to multiple lineages including osteoblast/osteocyte, adipose, muscle, and chondrocytes *in vitro* and formed bony nodules *in vivo*.²⁴ While demonstrating *in vivo* rescue of a non-union fracture rat tibia model with the use of purified human pericytes derived from adipose tissue, the key mechanism was that of the pericyte trophic function, and the role direct ossification was not clear.⁹³ Another study implanted pericytes within muscle and showed ectopic bone

formation.^{24,92} Incorporation of human purified perivascular cells have also been observed with a murine critical sized calvarial bone defect.⁹²

Muscle

Fractures are typically traumatic injuries that involve damage to the nearby muscle tissue in addition to the bone. The importance of skeletal muscle to fracture repair has long been appreciated in a clinical setting where open fractures are classified according to the Gustilo-Anderson scale, which characterizes severity of the fracture almost solely upon the extent of the soft tissue (muscle) damage.^{132,133} Muscle is known to be highly permissive for bone formation. This can be capitalized upon therapeutically by applying muscle or fasciocutaneous flaps to improve surgical outcomes of open fractures.¹³⁴ Conversely, diseases such as fibrodysplasia ossificans progressive, polytraumatic injuries (burns or traumatic brain injury), and some surgeries can lead to unwanted bone formation in the muscle.

Despite the long standing clinical consideration of muscle in fracture healing, the underlying molecular and cellular mechanisms by which muscle contributes to fracture healing are not well understood. This is due in part to the complex and multidimensional cross-talk between muscle and bone. For example, muscle influences fracture healing indirectly by providing a vascular bed in close proximity and by modulating load on the bone. The role of the vasculature was covered in detail previously, and it was described briefly how the periosteal progenitor cells appear to be mechanosensitive since fracture fixation and local stability contributes to differentiation patterns. The influence of load can also impact healing independent of orthopaedic hardware as studies have shown fracture healing is delayed by muscle paralysis, disuse atrophy, or immobilization.^{135–138} Dissecting the cellular mechanisms that transmit mechanical signals is an active area of research that requires significantly more work, but recent work suggests that the primary cilium is a sensory organelle on cells that can sense and transduce load,^{139,140} and that both TGF β ¹⁴¹ and connexin43^{142–145} are mechanosensitive pathways in the skeleton.

Muscle may also contribute to fracture healing more directly, by providing either cells or paracrine stimuli to promote healing. Multiple subpopulations of progenitor cells have been described in skeletal muscle. The satellite stem cell, originally described in 1961 by Mauro¹⁴⁶, is located between the basal lamina and sarcolemma of myofibers and reliably identified by expression of the paired box transcription factor Pax7.^{146,147} Satellite cells are traditionally considered unipotent myogenic precursor cells that remain quiescent until triggered into a regenerative state by an external stimulus to then generate myoblasts that fuse to form new multinucleated myofibers. Importantly, stemness has been experimentally evaluated with transplantation and lineage tracing studies to show satellite cells are capable of replenishing the existing stem cell pool via self-renewal.^{148–151} Genetic deletion of Pax7 satellite cells in adult mice entirely blocks regenerative myogenesis^{152–154} and also severely impairs fracture healing¹⁵⁵. In fracture healing, Pax7 ablation acts primarily to support the periosteum through production of key osteogenic growth factors (bone morphogenetic protein, insulin-like growth factor 1, and fibroblast growth factor 2).¹⁵⁵ The muscle secretome has been expanded to identify over 200 proteins many of which are key for

fracture repair and modulating inflammation.^{156,157} Interestingly, transplanted muscle, and to a lesser extent transplanted Pax7 satellite cells, were also shown to contribute to the fracture callus as chondrocytes.¹⁵⁵ However, the Pax7 satellite cells do not contribute to HO formation.¹⁵⁸ Indicating a possible multipotency of the Pax7 cells under the correct conditions of injury.

In addition to the satellite cell, recent evidence supports non-satellite skeletal muscle-resident mesenchymal progenitors cells exhibit multilineage potential. In 2008, Gharaibeh *et al*/experimentally isolated a muscle derived stem cell (MDSC) population of slowly adhering cells by preplating digested muscle biopsies.²² These cells have been shown to have a similar marker profile with bone marrow derived MSCs and pericytes (CD73, CD90, CD105, CD44, CD56, CD146 high: CD45 negative) and exhibit myogenic, osteogenic, chondrogenic, and adipogenic capacities *in vitro*.¹⁵⁹ MDSCs have been shown to be effective for bone regeneration when supplemented with exogenous BMP, but an endogenous role of MDSCs in bone formation has not been demonstrated.^{160–162}

Later, in 2010, two groups identified a skeletal muscle resident progenitor cell with fibro/adipogenic potential (FAPs) that cumulatively can be identified as PDGFR α +, Sca1+, CD34+, CD45-, CD31-, SM/C2.6-.^{163,164} While these cells were initially characterized for giving rise to fibroblasts and adipocytes *in vivo*, experiments in a Tie2-CreERT::GFP reporter revealed that GFP+, PDGFR α +, Sca1+ cells give rise to cartilage and bone in an experimental model of heterotopic ossification.¹⁶⁴ In fracture healing it has been shown that a muscle-derived cell contributes to fracture healing, but the identity of that cell is unclear.¹⁵⁵ Taken together, these data suggest both a paracrine and possibly direct cellular role for muscle during fracture healing.

Genetic mechanism for studying stem cells *in vivo*

Modern genetics has made it possible to use murine models to study the role of stem cells in regeneration and injury. Based on the current data, there are a number of potential progenitor populations that should to be considered for their role in fracture repair, but there is an evolving understanding of their functional role that justifies continued research efforts. Specifically, as more markers are discovered the overlap between these cell types, both in their nomenclature and at functional level, is unclear. Even more importantly, we need to think of the cells more cross-functionally, beyond individual contributions and take into consideration their interaction with other cell types. In Table 2 below we compile many of the mice that have been used to study progenitor populations.

Acknowledgments

This publication was supported financially by the National Institutes of Health (NIH) through the National Center for Advancing Translational Sciences Grant Numbers UCSF-UL1TR000004 and BU-1UL1TR001430, the National Institute of Arthritis and Musculoskeletal and Skin (NIAMS) R01-AR056637 and K99AR068582, the AO Foundation Start-Up Grant (CSB, #S-14-114B), the UCSF Core Center for Musculoskeletal Biology and Medicine Grant Number P30AR066262, and the Research Evaluation & Allocation Committee (REAC) UCSF School of Medicine. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We would like to thank Emily Moore at Columbia University and Dr. Johnny Huard at the Stedman Phillipon Research Institute and UT Health for providing helpful information and discussion that contributed to this

review. The authors acknowledge institutional support from the UCSF/ZSFG Orthopaedic Trauma Institute and Boston University School of Medicine Department of Orthopaedic Surgery.

References

1. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. *Nature*. 2007; 448:313–317. [nature05934 \[pii\]](#). DOI: 10.1038/nature05934 [PubMed: 17554338]
2. Yu J, et al. Human induced pluripotent stem cells free of vector and transgene sequences. *Science*. 2009; 324:797–801. DOI: 10.1126/science.1172482 [PubMed: 19325077]
3. Bianco P, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. *Nature medicine*. 2013; 19:35–42. DOI: 10.1038/nm.3028
4. Urist MR. Bone: formation by autoinduction. *Science*. 1965; 150:893–899. [PubMed: 5319761]
5. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. *Trends in biotechnology*. 2001; 19:255–265. [PubMed: 11412949]
6. Urist MR, Mikulski A, Lietze A. Solubilized and insolubilized bone morphogenetic protein. *Proc Natl Acad Sci U S A*. 1979; 76:1828–1832. [PubMed: 221908]
7. Tavassoli M, Crosby WH. Transplantation of marrow to extramedullary sites. *Science*. 1968; 161:54–56. [PubMed: 4871792]
8. Friedenstein AJ. Precursor cells of mechanocytes. *International Review of Cytology*. 1976; 47:327–355. [PubMed: 11195]
9. Friedenstein AJ. Stromal mechanisms of bone marrow: cloning in vitro and retransplantation in vivo. *Haematol Blood Transfus*. 1980; 25:19–29. [PubMed: 7021339]
10. Friedenstein AJ, Chailakhyan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet*. 1970; 3:393–403. [PubMed: 5523063]
11. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. *Cell Tissue Kinet*. 1987; 20:263–272. [PubMed: 3690622]
12. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. *Transplantation*. 1974; 17:331–340. [PubMed: 4150881]
13. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation*. 1968; 6:230–247. [PubMed: 5654088]
14. Friedenstein AJ, Piatetzky S II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. *J Embryol Exp Morphol*. 1966; 16:381–390. [PubMed: 5336210]
15. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006; 8:315–317. [Q2183N8UT042W62H \[pii\]](#). DOI: 10.1080/14653240600855905 [PubMed: 16923606]
16. Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. *Science*. 1999; 284:143–147. [PubMed: 10102814]
17. Zuk PA, et al. Human adipose tissue is a source of multipotent stem cells. *Molecular biology of the cell*. 2002; 13:4279–4295. DOI: 10.1091/mbc.E02-02-0105 [PubMed: 12475952]
18. De Bari C, et al. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. *Arthritis and rheumatism*. 2006; 54:1209–1221. DOI: 10.1002/art.21753 [PubMed: 16575900]
19. Miura Y, Fitzsimmons JS, Commisso CN, Galloway SH, O'Driscoll SW. Enhancement of periosteal chondrogenesis in vitro. Dose-response for transforming growth factor-beta 1 (TGF-beta 1). *Clinical orthopaedics and related research*. 1994:271–280.
20. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis and rheumatism*. 2001; 44:1928–1942. DOI: 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P [PubMed: 11508446]

21. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. *Arthritis and rheumatism*. 2005; 52:2521–2529. DOI: 10.1002/art.21212 [PubMed: 16052568]
22. Gharaibeh B, et al. Isolation of a slowly adhering cell fraction containing stem cells from murine skeletal muscle by the preplate technique. *Nature protocols*. 2008; 3:1501–1509. DOI: 10.1038/nprot.2008.142 [PubMed: 18772878]
23. Lavasani M, et al. Isolation of muscle-derived stem/progenitor cells based on adhesion characteristics to collagen-coated surfaces. *Methods Mol Biol*. 2013; 976:53–65. DOI: 10.1007/978-1-62703-317-6_5 [PubMed: 23400434]
24. Crisan M, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell stem cell*. 2008; 3:301–313. S1934-5909(08)00337-8 [pii]. DOI: 10.1016/j.stem.2008.07.003 [PubMed: 18786417]
25. Crisan M, et al. Perivascular multipotent progenitor cells in human organs. *Annals of the New York Academy of Sciences*. 2009; 1176:118–123. DOI: 10.1111/j.1749-6632.2009.04967.x [PubMed: 19796239]
26. Caplan AI. All MSCs are pericytes? *Cell stem cell*. 2008; 3:229–230. DOI: 10.1016/j.stem.2008.08.008 [PubMed: 18786406]
- 27*. Sacchetti B, et al. No Identical “Mesenchymal Stem Cells” at Different Times and Sites: Human Committed Progenitors of Distinct Origin and Differentiation Potential Are Incorporated as Adventitial Cells in Microvessels. *Stem Cell Reports*. 2016; 6:897–913. This study suggests that there are tissue specific progenitor cell populations that are not pericytes but do contribute to pericyte fate. DOI: 10.1016/j.stemcr.2016.05.011 [PubMed: 27304917]
28. Noel D, et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. *Exp Cell Res*. 2008; 314:1575–1584. DOI: 10.1016/j.yexcr.2007.12.022 [PubMed: 18325494]
29. Kawanami A, Matsushita T, Chan YY, Murakami S. Mice expressing GFP and CreER in osteochondro progenitor cells in the periosteum. *Biochemical and biophysical research communications*. 2009; 386:477–482. DOI: 10.1016/j.bbrc.2009.06.059 [PubMed: 19538944]
30. Park D, et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. *Cell stem cell*. 2012; 10:259–272. DOI: 10.1016/j.stem.2012.02.003 [PubMed: 22385654]
31. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. *Cell stem cell*. 2014; 15:154–168. DOI: 10.1016/j.stem.2014.06.008 [PubMed: 24953181]
32. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. *Journal of cellular biochemistry*. 2006; 98:1076–1084. DOI: 10.1002/jcb.20886 [PubMed: 16619257]
33. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. *Journal of cellular physiology*. 1996; 166:585–592. 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6. [pii]. [PubMed: 8600162]
34. Caplan AI, Correa D. The MSC: an injury drugstore. *Cell stem cell*. 2011; 9:11–15. DOI: 10.1016/j.stem.2011.06.008 [PubMed: 21726829]
35. da Meirelles LS, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. *Cytokine Growth Factor Rev*. 2009; 20:419–427. DOI: 10.1016/j.cytogfr.2009.10.002 [PubMed: 19926330]
36. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood*. 2005; 105:1815–1822. 2004-04-1559 [pii]. DOI: 10.1182/blood-2004-04-1559 [PubMed: 15494428]
37. Bai L, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. *Glia*. 2009; 57:1192–1203. DOI: 10.1002/glia.20841 [PubMed: 19191336]
38. Caplan AI, Sorrell JM. The MSC curtain that stops the immune system. *Immunol Lett*. 2015; 168:136–139. DOI: 10.1016/j.imlet.2015.06.005 [PubMed: 26079607]

39. Guimaraes-Camboa N, et al. Pericytes of Multiple Organs Do Not Behave as Mesenchymal Stem Cells In Vivo. *Cell stem cell*. 2017; 20:345–359 e345. DOI: 10.1016/j.stem.2016.12.006 [PubMed: 28111199]
40. Caplan AI. Mesenchymal Stem Cells: Time to Change the Name! *Stem cells translational medicine*. 2017; 6:1445–1451. DOI: 10.1002/sctm.17-0051 [PubMed: 28452204]
41. Caplan AI. MSCs: The Sentinel and Safe-Guards of Injury. *Journal of cellular physiology*. 2016; 231:1413–1416. DOI: 10.1002/jcp.25255 [PubMed: 26565391]
42. Wang X, et al. MMP9 regulates the cellular response to inflammation after skeletal injury. *Bone*. 2013; 52:111–119. DOI: 10.1016/j.bone.2012.09.018 [PubMed: 23010105]
43. Xing Z, et al. Multiple roles for CCR2 during fracture healing. *Disease models & mechanisms*. 2010; 3:451–458. dmm.003186 [pii]. DOI: 10.1242/dmm.003186 [PubMed: 20354109]
44. Xing Z, Lu C, Hu D, Miclau T 3rd, Marcucio RS. Rejuvenation of the inflammatory system stimulates fracture repair in aged mice. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2010; 28:1000–1006. DOI: 10.1002/jor.21087 [PubMed: 20108320]
45. Abou-Khalil R, et al. Delayed bone regeneration is linked to chronic inflammation in murine muscular dystrophy. *J Bone Miner Res*. 2014; 29:304–315. DOI: 10.1002/jbmr.2038 [PubMed: 23857747]
46. Ozaki A, Tsunoda M, Kinoshita S, Saura R. Role of fracture hematoma and periosteum during fracture healing in rats: interaction of fracture hematoma and the periosteum in the initial step of the healing process. *J Orthop Sci*. 2000; 5:64–70. [PubMed: 10664441]
47. Baht GS, et al. Erratum: Exposure to a youthful circulation rejuvenates bone repair through modulation of beta-catenin. *Nature communications*. 2015; 6:7761.
48. Colnot C. Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. *J Bone Miner Res*. 2009; 24:274–282. [pii]. DOI: 10.1359/jbmr.08100310.1359/jbmr.081003 [PubMed: 18847330]
- 49*. Murao H, Yamamoto K, Matsuda S, Akiyama H. Periosteal cells are a major source of soft callus in bone fracture. *J Bone Miner Metab*. 2013; 31:390–398. Identified the Prx1 population of cells located in the periosteum is a key contributor of cells for fracture repair. DOI: 10.1007/s00774-013-0429-x [PubMed: 23475152]
50. Matthews BG, et al. Analysis of alphaSMA-labeled progenitor cell commitment identifies notch signaling as an important pathway in fracture healing. *J Bone Miner Res*. 2014; 29:1283–1294. DOI: 10.1002/jbmr.2140 [PubMed: 24190076]
51. Bais M, et al. Transcriptional analysis of fracture healing and the induction of embryonic stem cell-related genes. *PloS one*. 2009; 4:e5393. [PubMed: 19415118]
52. Yu NY, O'Brien CA, Slapetova I, Whan RM, Knothe Tate ML. Live Tissue Imaging to Elucidate Mechanical Modulation of Stem Cell Niche Quiescence. *Stem cells translational medicine*. 2017; 6:285–292. DOI: 10.5966/sctm.2015-0306 [PubMed: 28170186]
53. Le AX, Miclau T, Hu D, Helms JA. Molecular aspects of healing in stabilized and non-stabilized fractures. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2001; 19:78–84. S0736-0266(00)00006-1 [pii]. DOI: 10.1016/S0736-0266(00)00006-1 [PubMed: 11332624]
54. Knothe Tate ML, Falls TD, McBride SH, Atit R, Knothe UR. Mechanical modulation of osteochondroprogenitor cell fate. *Int J Biochem Cell Biol*. 2008; 40:2720–2738. DOI: 10.1016/j.biocel.2008.05.011 [PubMed: 18620888]
55. Burke DP, Kelly DJ. Substrate stiffness and oxygen as regulators of stem cell differentiation during skeletal tissue regeneration: a mechanobiological model. *PloS one*. 2012; 7:e40737. [PubMed: 22911707]
56. Loi F, et al. Inflammation, fracture and bone repair. *Bone*. 2016; 86:119–130. DOI: 10.1016/j.bone.2016.02.020 [PubMed: 26946132]
57. Tsang KY, Chan D, Cheah KS. Fate of growth plate hypertrophic chondrocytes: Death or lineage extension? *Development, growth & differentiation*. 2015; 57:179–192. DOI: 10.1111/dgd.12203

58. Shapiro IM, Adams CS, Freeman T, Srinivas V. Fate of the hypertrophic chondrocyte: microenvironmental perspectives on apoptosis and survival in the epiphyseal growth plate. *Birth defects research. Part C, Embryo today : reviews*. 2005; 75:330–339. DOI: 10.1002/bdrc.20057
59. Bahney CS, et al. Stem cell-derived endochondral cartilage stimulates bone healing by tissue transformation. *J Bone Miner Res*. 2014; 29:1269–1282. DOI: 10.1002/jbmr.2148 [PubMed: 24259230]
60. Hu DP, et al. Cartilage to bone transformation during fracture healing is coordinated by the invading vasculature and induction of the core pluripotency genes. *Development*. 2017; 144:221–234. DOI: 10.1242/dev.130807 [PubMed: 28096214]
61. Yang L, Tsang KY, Tang HC, Chan D, Cheah KS. Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation. *Proc Natl Acad Sci U S A*. 2014
62. Zhou X, et al. Chondrocytes Transdifferentiate into Osteoblasts in Endochondral Bone during Development, Postnatal Growth and Fracture Healing in Mice. *PLoS genetics*. 2014; 10:e1004820. [PubMed: 25474590]
63. Park J, et al. Dual pathways to endochondral osteoblasts: a novel chondrocyte-derived osteoprogenitor cell identified in hypertrophic cartilage. *Biology open*. 2015; 4:608–621. DOI: 10.1242/bio.201411031 [PubMed: 25882555]
64. Jing Y, et al. Chondrocytes Directly Transform into Bone Cells in Mandibular Condyle Growth. *Journal of dental research*. 2015; 94:1668–1675. DOI: 10.1177/0022034515598135 [PubMed: 26341973]
65. Houben A, et al. beta-catenin activity in late hypertrophic chondrocytes locally orchestrates osteoblastogenesis and osteoclastogenesis. *Development*. 2016; 143:3826–3838. DOI: 10.1242/dev.137489 [PubMed: 27621061]
66. Maes C, et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. *Dev Cell*. 2010; 19:329–344. S1534-5807(10)00338-2 [pii]. DOI: 10.1016/j.devcel.2010.07.010 [PubMed: 20708594]
67. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? *The American journal of pathology*. 2007; 170:427–435. DOI: 10.2353/ajpath.2007.060834 [PubMed: 17255310]
68. Matsuoka K, Park KA, Ito M, Ikeda K, Takeshita S. Osteoclast-derived complement component 3a stimulates osteoblast differentiation. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2014; 29:1522–1530. DOI: 10.1002/jbmr.2187
69. Tang Y, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. *Nat Med*. 2009; 15:757–765. DOI: 10.1038/nm.1979 [PubMed: 19584867]
70. Krum SA, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. *The EMBO journal*. 2008; 27:535–545. DOI: 10.1038/sj.emboj.7601984 [PubMed: 18219273]
71. Evans SF, et al. Periosteum, bone's "smart" bounding membrane, exhibits direction-dependent permeability. *J Bone Miner Res*. 2013; 28:608–617. DOI: 10.1002/jbmr.1777 [PubMed: 23018813]
72. Moore SR, et al. Translating Periosteum's Regenerative Power: Insights From Quantitative Analysis of Tissue Genesis With a Periosteum Substitute Implant. *Stem cells translational medicine*. 2016; 5:1739–1749. DOI: 10.5966/sctm.2016-0004 [PubMed: 27465072]
73. Utvag SE, Grundnes O, Reikeraas O. Effects of periosteal stripping on healing of segmental fractures in rats. *Journal of orthopaedic trauma*. 1996; 10:279–284. [PubMed: 8723407]
74. Caballero M, Pappa AK, Roden KS, Krochmal DJ, van Aalst JA. Osteoinduction of umbilical cord and palate periosteum-derived mesenchymal stem cells on poly(lactic-co-glycolic) acid nanomicrofibers. *Ann Plast Surg*. 2014; 72:S176–183. DOI: 10.1097/SAP.0000000000000107 [PubMed: 24691324]
75. Chang H, Docheva D, Knothe UR, Knothe Tate ML. Arthritic periosteal tissue from joint replacement surgery: a novel, autologous source of stem cells. *Stem cells translational medicine*. 2014; 3:308–317. DOI: 10.5966/sctm.2013-0056 [PubMed: 24477075]

76. Yu YY, et al. Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair. *Bone*. 2010; 46:841–851. S8756-3282(09)02017-1 [pii]. DOI: 10.1016/j.bone.2009.11.005 [PubMed: 19913648]
77. Morgan EF, et al. BMPRI1A antagonist differentially affects cartilage and bone formation during fracture healing. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2016; 34:2096–2105. DOI: 10.1002/jor.23233 [PubMed: 26990682]
78. Ouyang Z, et al. Prx1 and 3.2kb Col1a1 promoters target distinct bone cell populations in transgenic mice. *Bone*. 2013
79. Logan M, et al. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prx1 enhancer. *Genesis*. 2002; 33:77–80. DOI: 10.1002/gene.10092 [PubMed: 12112875]
80. Martin JF, Olson EN. Identification of a prx1 limb enhancer. *Genesis*. 2000; 26:225–229. [PubMed: 10748458]
81. Tsuji K, et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. *Nature genetics*. 2006; 38:1424–1429. DOI: 10.1038/ng1916 [PubMed: 17099713]
- 82*. Grcevic D, et al. In vivo fate mapping identifies mesenchymal progenitor cells. *Stem Cells*. 2012; 30:187–196. Described how lineage tracking studies can be used to identify a novel stem/progenitor cell population that contributes to fracture repair. DOI: 10.1002/stem.780 [PubMed: 22083974]
83. Kumagai K, Vasanji A, Drazba JA, Butler RS, Muschler GF. Circulating cells with osteogenic potential are physiologically mobilized into the fracture healing site in the parabiotic mice model. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2008; 26:165–175. DOI: 10.1002/jor.20477 [PubMed: 17729300]
84. Caplan AI. Why are MSCs therapeutic? New data: new insight. *The Journal of pathology*. 2009; 217:318–324. DOI: 10.1002/path.2469 [PubMed: 19023885]
85. Bianco P, Gehron Robey P, Saggio I, Riminucci M. “Mesenchymal” stem cells in human bone marrow (skeletal stem cells) - a critical discussion of their nature, identity, and significance in incurable skeletal disease. *Hum Gene Ther*. 2010
86. Prockop DJ. “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). *Clin Pharmacol Ther*. 2007; 82:241–243. 6100313 [pii]. DOI: 10.1038/sj.clpt.6100313 [PubMed: 17700588]
87. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. *Mol Ther*. 2009; 17:939–946. mt200962 [pii]. DOI: 10.1038/mt.2009.62 [PubMed: 19337235]
88. Li Y, et al. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. *Glia*. 2005; 49:407–417. DOI: 10.1002/glia.20126 [PubMed: 15540231]
89. Chen J, et al. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. *J Neurosci Res*. 2003; 73:778–786. DOI: 10.1002/jnr.10691 [PubMed: 12949903]
90. Horwitz EM, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. *Proc Natl Acad Sci U S A*. 2002; 99:8932–8937. [pii]. DOI: 10.1073/pnas.1322523999/13/8932 [PubMed: 12084934]
91. Laflamme MA, Murry CE. Regenerating the heart. *Nat Biotechnol*. 2005; 23:845–856. nbt1117 [pii]. DOI: 10.1038/nbt1117 [PubMed: 16003373]
92. James AW, et al. An abundant perivascular source of stem cells for bone tissue engineering. *Stem cells translational medicine*. 2012; 1:673–684. DOI: 10.5966/sctm.2012-0053 [PubMed: 23197874]
93. Tawonsawatruk T, et al. Adipose derived pericytes rescue fractures from a failure of healing--non-union. *Sci Rep*. 2016; 6:22779. [PubMed: 26997456]
94. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. *The Journal of pathology*. 2013; 229:176–185. DOI: 10.1002/path.4133 [PubMed: 23096265]

95. Dayan V, et al. Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. *Basic Res Cardiol*. 2011; 106:1299–1310. DOI: 10.1007/s00395-011-0221-9 [PubMed: 21901289]
96. English K. Mechanisms of mesenchymal stromal cell immunomodulation. *Immunol Cell Biol*. 2013; 91:19–26. DOI: 10.1038/icb.2012.56 [PubMed: 23090487]
97. Gerstenfeld LC, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. *Journal of cellular biochemistry*. 2003; 88:873–884. DOI: 10.1002/jcb.10435 [PubMed: 12616527]
98. Kronenberg HM. Developmental regulation of the growth plate. *Nature*. 2003; 423:332–336. [pii]. DOI: 10.1038/nature01657 [PubMed: 12748651]
99. Pritchard JJ, Ruzicka AJ. Comparison of fracture repair in the frog, lizard and rat. *Journal of anatomy*. 1950; 84:236–261. [PubMed: 15436329]
100. Roach HI. Trans-differentiation of hypertrophic chondrocytes into cells capable of producing a mineralized bone matrix. *Bone Miner*. 1992; 19:1–20. [PubMed: 1422302]
101. Roach HI. New aspects of endochondral ossification in the chick: chondrocyte apoptosis, bone formation by former chondrocytes, and acid phosphatase activity in the endochondral bone matrix. *J Bone Miner Res*. 1997; 12:795–805. DOI: 10.1359/jbmr.1997.12.5.795 [PubMed: 9144346]
102. Roach HI, Erenpreisa J. The phenotypic switch from chondrocytes to bone-forming cells involves asymmetric cell division and apoptosis. *Connective tissue research*. 1996; 35:85–91. [PubMed: 9084646]
103. Roach HI, Erenpreisa J, Aigner T. Osteogenic differentiation of hypertrophic chondrocytes involves asymmetric cell divisions and apoptosis. *The Journal of cell biology*. 1995; 131:483–494. [PubMed: 7593173]
104. Scammell BE, Roach HI. A new role for the chondrocyte in fracture repair: endochondral ossification includes direct bone formation by former chondrocytes. *J Bone Miner Res*. 1996; 11:737–745. DOI: 10.1002/jbmr.5650110604 [PubMed: 8725170]
105. Holtzer H, Abbott J, Lash J, Holtzer S. The Loss of Phenotypic Traits by Differentiated Cells in Vitro. I. Dedifferentiation of Cartilage Cells. *Proc Natl Acad Sci U S A*. 1960; 46:1533–1542. [PubMed: 16590779]
106. Benya PD, Shaffer JD. Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels. *Cell*. 1982; 30:215–224. [PubMed: 7127471]
107. Song L, Tuan RS. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. *FASEB J*. 2004; 18:980–982. [pii]. DOI: 10.1096/fj.03-1100fje03-1100fje [PubMed: 15084518]
108. Juuri E, et al. Sox2+ stem cells contribute to all epithelial lineages of the tooth via Sfrp5+ progenitors. *Dev Cell*. 2012; 23:317–328. DOI: 10.1016/j.devcel.2012.05.012 [PubMed: 22819339]
109. Emmerson E, et al. SOX2 regulates acinar cell development in the salivary gland. *Elife*. 2017; 6
110. Arnold K, et al. Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. *Cell stem cell*. 2011; 9:317–329. DOI: 10.1016/j.stem.2011.09.001 [PubMed: 21982232]
111. Suh H, et al. In vivo fate analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem cells in the adult hippocampus. *Cell stem cell*. 2007; 1:515–528. DOI: 10.1016/j.stem.2007.09.002 [PubMed: 18371391]
112. D'Amour KA, Gage FH. Genetic and functional differences between multipotent neural and pluripotent embryonic stem cells. *Proc Natl Acad Sci U S A*. 2003; 100(Suppl 1):11866–11872. DOI: 10.1073/pnas.1834200100 [PubMed: 12923297]
113. Yang G, et al. Osteogenic fate of hypertrophic chondrocytes. *Cell research*. 2014; 24:1266–1269. DOI: 10.1038/cr.2014.111 [PubMed: 25145361]
114. Roach HI, Clarke NM. Physiological cell death of chondrocytes in vivo is not confined to apoptosis. New observations on the mammalian growth plate. *The Journal of bone and joint surgery*. British volume. 2000; 82:601–613. [PubMed: 10855892]

115. Gerstenfeld LC, Shapiro FD. Expression of bone-specific genes by hypertrophic chondrocytes: implication of the complex functions of the hypertrophic chondrocyte during endochondral bone development. *Journal of cellular biochemistry*. 1996; 62:1–9. DOI: 10.1002/(SICI)1097-4644(199607)62:1<1::AID-JCB1>3.0.CO;2-X [PubMed: 8836870]
116. Lian JB, McKee MD, Todd AM, Gerstenfeld LC. Induction of bone-related proteins, osteocalcin and osteopontin, and their matrix ultrastructural localization with development of chondrocyte hypertrophy in vitro. *Journal of cellular biochemistry*. 1993; 52:206–219. DOI: 10.1002/jcb.240520212 [PubMed: 8366137]
117. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrughe B. Sox9 is required for cartilage formation. *Nature genetics*. 1999; 22:85–89. DOI: 10.1038/8792 [PubMed: 10319868]
118. Topol L, Chen W, Song H, Day TF, Yang Y. Sox9 inhibits Wnt signaling by promoting beta-catenin phosphorylation in the nucleus. *The Journal of biological chemistry*. 2009; 284:3323–3333. DOI: 10.1074/jbc.M808048200 [PubMed: 19047045]
119. Zhou G, et al. Dominance of SOX9 function over RUNX2 during skeletogenesis. *Proc Natl Acad Sci U S A*. 2006; 103:19004–19009. DOI: 10.1073/pnas.0605170103 [PubMed: 17142326]
120. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. *Dev Cell*. 2005; 8:727–738. DOI: 10.1016/j.devcel.2005.02.013 [PubMed: 15866163]
121. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. *Dev Cell*. 2005; 8:739–750. DOI: 10.1016/j.devcel.2005.03.016 [PubMed: 15866164]
122. Gaur T, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. *The Journal of biological chemistry*. 2005; 280:33132–33140. DOI: 10.1074/jbc.M500608200 [PubMed: 16043491]
123. Kakar S, et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. *J Bone Miner Res*. 2007; 22:1903–1912. DOI: 10.1359/jbmr.070724 [PubMed: 17680724]
124. Lu C, et al. Effect of age on vascularization during fracture repair. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2008; 26:1384–1389. DOI: 10.1002/jor.20667 [PubMed: 18464248]
125. Lu C, Marcucio R, Miclau T. Assessing angiogenesis during fracture healing. *The Iowa orthopaedic journal*. 2006; 26:17–26. [PubMed: 16789443]
126. Dickson KF, Katzman S, Paiement G. The importance of the blood supply in the healing of tibial fractures. *Contemp Orthop*. 1995; 30:489–493. [PubMed: 10150380]
127. Matsubara H, et al. Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis. *Bone*. 2012; 51:168–180. DOI: 10.1016/j.bone.2012.02.017 [PubMed: 22391215]
128. Chen CW, et al. Perivascular multi-lineage progenitor cells in human organs: regenerative units, cytokine sources or both? *Cytokine Growth Factor Rev*. 2009; 20:429–434. DOI: 10.1016/j.cytogfr.2009.10.014 [PubMed: 19926515]
129. Gerl K, et al. Inducible glomerular erythropoietin production in the adult kidney. *Kidney Int*. 2015; 88:1345–1355. DOI: 10.1038/ki.2015.274 [PubMed: 26398496]
130. Zhu X, et al. Age-dependent fate and lineage restriction of single NG2 cells. *Development*. 2011; 138:745–753. DOI: 10.1242/dev.047951 [PubMed: 21266410]
131. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev Cell*. 2011; 21:193–215. DOI: 10.1016/j.devcel.2011.07.001 [PubMed: 21839917]
132. Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. *The Journal of trauma*. 1984; 24:742–746. [PubMed: 6471139]
133. Kim PH, Leopold SS. In brief: Gustilo-Anderson classification. [corrected]. *Clinical orthopaedics and related research*. 2012; 470:3270–3274. DOI: 10.1007/s11999-012-2376-6 [PubMed: 22569719]
134. Yazar S, Lin CH, Lin YT, Ulusal AE, Wei FC. Outcome comparison between free muscle and free fasciocutaneous flaps for reconstruction of distal third and ankle traumatic open tibial fractures.

- Plastic and reconstructive surgery. 2006; 117:2468–2475. discussion 2476–2467. DOI: 10.1097/01.prs.0000224304.56885.c2 [PubMed: 16772958]
135. Rot C, Stern T, Blecher R, Friesem B, Zelzer E. A mechanical Jack-like Mechanism drives spontaneous fracture healing in neonatal mice. *Dev Cell*. 2014; 31:159–170. DOI: 10.1016/j.devcel.2014.08.026 [PubMed: 25373776]
 136. Poliachik SL, Bain SD, Threet D, Huber P, Gross TS. Transient muscle paralysis disrupts bone homeostasis by rapid degradation of bone morphology. *Bone*. 2010; 46:18–23. DOI: 10.1016/j.bone.2009.10.025 [PubMed: 19857614]
 137. Aliprantis AO, et al. Transient muscle paralysis degrades bone via rapid osteoclastogenesis. *FASEB J*. 2012; 26:1110–1118. DOI: 10.1096/fj.11-196642 [PubMed: 22125315]
 138. Hao Y, Ma Y, Wang X, Jin F, Ge S. Short-term muscle atrophy caused by botulinum toxin-A local injection impairs fracture healing in the rat femur. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2012; 30:574–580. DOI: 10.1002/jor.21553 [PubMed: 21919046]
 139. Malone AM, et al. Primary cilia mediate mechanosensing in bone cells by a calcium-independent mechanism. *Proc Natl Acad Sci U S A*. 2007; 104:13325–13330. DOI: 10.1073/pnas.0700636104 [PubMed: 17673554]
 140. Deren ME, Yang X, Guan Y, Chen Q. Biological and Chemical Removal of Primary Cilia Affects Mechanical Activation of Chondrogenesis Markers in Chondroprogenitors and Hypertrophic Chondrocytes. *Int J Mol Sci*. 2016; 17:188. [PubMed: 26861287]
 141. Rys JP, Monteiro DA, Alliston T. Mechanobiology of TGFbeta signaling in the skeleton. *Matrix Biol*. 2016; 52–54:413–425. DOI: 10.1016/j.matbio.2016.02.002
 142. Grimston SK, Watkins MP, Brodt MD, Silva MJ, Civitelli R. Enhanced periosteal and endocortical responses to axial tibial compression loading in conditional connexin43 deficient mice. *PLoS one*. 2012; 7:e44222. [PubMed: 22970183]
 143. Grimston SK, et al. Connexin43 deficiency reduces the sensitivity of cortical bone to the effects of muscle paralysis. *J Bone Miner Res*. 2011; 26:2151–2160. DOI: 10.1002/jbmr.425 [PubMed: 21590735]
 144. Grimston SK, Brodt MD, Silva MJ, Civitelli R. Attenuated response to in vivo mechanical loading in mice with conditional osteoblast ablation of the connexin43 gene (*Gja1*). *J Bone Miner Res*. 2008; 23:879–886. DOI: 10.1359/jbmr.080222 [PubMed: 18282131]
 145. Grimston SK, et al. Role of connexin43 in osteoblast response to physical load. *Annals of the New York Academy of Sciences*. 2006; 1068:214–224. DOI: 10.1196/annals.1346.023 [PubMed: 16831921]
 146. AM. Satellite cells of skeletal muscle fibers. *J Biochem Biophys Cytol*. 1961; 9:493–398.
 147. Seale P, et al. Pax7 is required for the specification of myogenic satellite cells. *Cell*. 2000; 102:777–786. [PubMed: 11030621]
 148. Kuang S, Kuroda K, Le Grand F, Rudnicki MA. Asymmetric self-renewal and commitment of satellite stem cells in muscle. *Cell*. 2007; 129:999–1010. DOI: 10.1016/j.cell.2007.03.044 [PubMed: 17540178]
 149. Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM. Self-renewal and expansion of single transplanted muscle stem cells. *Nature*. 2008; 456:502–506. DOI: 10.1038/nature07384 [PubMed: 18806774]
 150. Montarras D, et al. Direct isolation of satellite cells for skeletal muscle regeneration. *Science*. 2005; 309:2064–2067. DOI: 10.1126/science.1114758 [PubMed: 16141372]
 151. Dellavalle A, et al. Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. *Nature communications*. 2011; 2:499.
 152. Sambasivan R, et al. Pax7-expressing satellite cells are indispensable for adult skeletal muscle regeneration. *Development*. 2011; 138:3647–3656. DOI: 10.1242/dev.067587 [PubMed: 21828093]
 153. Lepper C, Partridge TA, Fan CM. An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration. *Development*. 2011; 138:3639–3646. DOI: 10.1242/dev.067595 [PubMed: 21828092]

154. Murphy MM, Lawson JA, Mathew SJ, Hutcheson DA, Kardon G. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. *Development*. 2011; 138:3625–3637. DOI: 10.1242/dev.064162 [PubMed: 21828091]
155. Abou-Khalil R, et al. Role of muscle stem cells during skeletal regeneration. *Stem Cells*. 2015; 33:1501–1511. DOI: 10.1002/stem.1945 [PubMed: 25594525]
156. Bortoluzzi S, Scannapieco P, Cestaro A, Danieli GA, Schiaffino S. Computational reconstruction of the human skeletal muscle secretome. *Proteins*. 2006; 62:776–792. DOI: 10.1002/prot.20803 [PubMed: 16342272]
157. Davis KM, et al. Muscle-bone interactions during fracture healing. *J Musculoskelet Neuronal Interact*. 2015; 15:1–9. [PubMed: 25730647]
158. Matthews BG, et al. Osteogenic potential of alpha smooth muscle actin expressing muscle resident progenitor cells. *Bone*. 2016; 84:69–77. DOI: 10.1016/j.bone.2015.12.010 [PubMed: 26721734]
159. Jankowski RJ, Deasy BM, Huard J. Muscle-derived stem cells. *Gene Ther*. 2002; 9:642–647. DOI: 10.1038/sj.gt.3301719 [PubMed: 12032710]
160. Gao X, et al. A comparison of bone regeneration with human mesenchymal stem cells and muscle-derived stem cells and the critical role of BMP. *Biomaterials*. 2014; 35:6859–6870. DOI: 10.1016/j.biomaterials.2014.04.113 [PubMed: 24856105]
161. Gao X, et al. Role of donor and host cells in muscle-derived stem cell-mediated bone repair: differentiation vs. paracrine effects. *FASEB J*. 2014; 28:3792–3809. DOI: 10.1096/fj.13-247965 [PubMed: 24843069]
162. Wright V, et al. BMP4-expressing muscle-derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. *Mol Ther*. 2002; 6:169–178. [PubMed: 12161183]
163. Joe AW, et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. *Nature cell biology*. 2010; 12:153–163. DOI: 10.1038/ncb2015 [PubMed: 20081841]
164. Wosczyzna MN, Biswas AA, Cogswell CA, Goldhamer DJ. Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. *J Bone Miner Res*. 2012; 27:1004–1017. DOI: 10.1002/jbmr.1562 [PubMed: 22307978]

Figure 1.

A drawing depicting different cell populations that contributes to fracture repair. The fracture callus and surrounding muscle along with areas of intramembranous (light red area), endochondral ossification (blue area), blood vessels, and nerves are indicated.

Table 1

MSC Cell Surface Markers

Marker	Description
CD29	Marker of MSCs recruited by Substance P to wounded sites
CD31	Endothelial/angiogenic progenitor cell marker
CD34	Early hematopoietic/endothelial progenitor cell marker
CD44	Early MSC marker putatively associated with Nanog expression
CD45	General hematopoietic stem cell marker
CD73	Marker of MSCs that demonstrate osteogenic capacity <i>in vitro</i>
CD105	Marker of MSCs that demonstrate osteogenic capacity <i>in vitro</i>
CD146	Marker of cells with ability to regenerate the hematopoietic stem cell niche and have osteogenic properties
CD271	Marker of MSCs that demonstrate osteogenic capacity <i>in vitro</i>
STRO-1	Marker of MSCs that demonstrate osteogenic capacity <i>in vitro</i>
Sca-1	Marker of MSCs that demonstrate osteogenic capacity <i>in vitro</i>
C-Kit	Marker of early and supposedly self-renewing endothelial progenitor cell
CXCR4	Receptor to SDF-1a

Table 2

Genetic labeling of stem cell populations

Cell Type	Cell Marker	In Vitro Differentiation	In Vivo Role in Fracture	Inducible Mice for Reporter/ Functional Studies	References
Stem Cells	Sox2	pluripotent	Expressed by hypertrophic chondrocytes KO delays FX healing	Sox2-CreER ⁺ ; Jax 017593	60, 108–111
	Oct4 (Pou5f1)		possibly expressed during FX healing	Oct4-MerCreMer; Jax 016829	59, 60
	Nangog		possibly expressed during FX healing	none to date	51, 60
Pericytes	PDGFR β neuro-glia 2 proteoglycan (NG2) alkaline phosphatase (AP)	bone, cartilage, fat, fibroblast, muscle, tendon (?)	Trophic (paracrine supply of growth factors)	PDGFR β -CreER ^{T2} ; Jax 029684, 030201 NG2-CreERT Tg: TN-AP-CreER ^{T2}	24, 25, 129 130 151
Periosteal Stem Cells	CD73 ⁺ , CD90 ⁺ , CD105 ⁺	bone, cartilage	Bi-potent osteochondral progenitor cells	Prx1-Cre; Jax 005584	29, 78–80
“MSCs”	myxovirus resistance-1 (Mx1) smooth muscle α -actin	? bone, cartilage, fat	Unipotent progenitor in bone marrow that gives rise to osteoblasts during FX healing Forms cartilage and bone in FX callus	Mx1-Cre; Jax 003556 α SMA-CreER ^{T2}	30 50, 51
Hypertrophic Chondrocytes	Type X Collagen	hypertrophic chondrocyte	Precursor to osteoblast in FX	Col10a1-CreER ^{T2}	61
	Osterix (Sp7)	hypertrophic chondrocyte/osteoblast	Preosteoblast in FX	SP7-CreERT	60, 66
FAPs/Muscle Derived Stem Cells	Scal ⁺ , CD34 ⁺ , CD45 ⁺ , PDGFR α	bone, cartilage, fat, fibroblast, muscle	May contribute directly to FX callus	PDGFR α -CreER ^{T2} ; Jax 018280	163, 164
Satellite Cells	Scal ⁺ , CD34 ⁺ , CD45 ⁺ , Myf5, Vcam, Pax7, Pax3	muscle	Trophic (paracrine supply of growth factors)	Pax7-CreER ^{T2} ; Jax 017763	146, 151–155
				Pax3-Cre; Jax 025663	155